Needham analyst David Saxon raised the firm’s price target on SI-Bone (SIBN) to $27 from $24 and keeps a Buy rating on the shares. The firm has also added the stock to its ‘Conviction List’, replacing ...

Canaccord analyst William Plovanic raised the firm’s price target on SI-Bone (SIBN) to $27 from $26 and keeps a Buy rating on the shares. The firm ...

Fintel reports that on December 16, 2025, Needham maintained coverage of SI-BONE (NasdaqGM:SIBN) with a Buy recommendation.

SI-BONE, Inc., a company focused on medical technologies for sacropelvic disorders, announced it will release its financial results for the fourth quarter and full year of 2024 on February 24, 2025, ...

SI-BONE reports strong revenue growth and improved financial metrics for Q4 2024 and FY 2024, achieving positive adjusted EBITDA. SI-BONE, Inc. reported strong financial results for the fourth quarter ...

SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be ...

Bank of America Securities analyst Craig Bijou reiterated a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $21.00. Craig Bijou has given his Buy rating due to a ...

Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective ...

Today, we take a look at SI-BONE, Inc., a medical device company focused on developing implantable devices for musculoskeletal disorders. The company is targeting a large potential market, delivers ...

Si-Bone makes the iFuse Implant System for the sacroiliac joint, found in the lower back. The company said it increased its surgeon base to 950 surgeons in the U.S. Revenue for Si-Bone was up 46% year ...